Enzootic bovine leukosis (EBL) is a chronic lymphosarcoma disease of cattle caused by bovine leukemia virus (BLV). No information is available concerning the epidemiology of BLV infection in yaks (Bos mutus). One thousand five hundred and eighty-four serum samples from 610 black yaks and 974 white yaks from Gansu province, northwest China, were collected between April 2013 and March 2014 and tested for BLV antibodies using a commercially available ELISA kit. The overall BLV seroprevalence in yaks was 21.09% (334/1584), with 24.26% (148/610) black yaks and 19.10% (186/974) white yaks yielding positive results. Risk factor analysis indicated that with the exception of breed (OR = 1.36, 95% CI = 1.06–1.73, P < 0.05), the age, region, gender, farm, and the numbers of pregnancies were not considered as risk factors for the presence of BLV in yaks included in this study. This is the first report of BLV infection in yaks in China, which provides information for controlling BLV infection in yaks.

Infection with bovine leukemia virus (BLV) leads to enzootic bovine leukosis, the most prevalent neoplastic disease in cattle. Due to the lack of commercially available vaccines, reliable eradication of the disease can be achieved through the testing and elimination of BLV antibody-positive animals. In this study, we developed a novel competitive ELISA (cELISA) to detect antibodies against BLV capsid protein p24. Recombinant p24 protein expressed by Escherichia coli, in combination with the monoclonal antibody 2G11 exhibiting exceptional performance, was used for the establishment of the cELISA. Receiver-operating characteristic curve analysis showed that the sensitivity and specificity of the assay were 98.85 % and 98.13 %, respectively. Furthermore, the established cELISA was specific for detecting BLV-specific antibodies, without cross-reactivity to antisera for six other bovine viruses. Significantly, experimental infection of cattle and sheep with BLV revealed that the cELISA accurately monitors seroconversion. In a performance evaluation, the established cELISA displayed a high agreement with Western blotting and the commercial BLV gp51 cELISA kit in the detection of 242 clinical samples, respectively. In conclusion, the novel p24 cELISA exhibited the potential to be a reliable and efficient diagnostic tool for BLV serological detection with a broad application prospect.

Bovine leukemia virus (BLV) is an enveloped virus, found worldwide that can infect cattle and induce many subclinical symptoms and malignant tumors. BLV infection causes severe economic losses in the cattle industry. The identification of BLV-infected cattle for segregation or elimination would be the most effective way to halt the spread of BLV infection on farms, owing to the lack of effective treatments and vaccines. Therefore, antibody detection against the viral glycoprotein gp51 is an effective method for diagnosing BLV-infected animals. In this study, ten different subregions of gp51 containing a common B cell epitope are vital for developing antigens as epitope-driven vaccine design and immunological assays. Such antigens were produced in Escherichia coli expression system to react with antibodies in the serum from BLV-infected cattle and compete for antigenicity. Recombinant His-gp5156–110 and gp5133–301(full) had the same sensitivity in BLV-positive sera, indicating that antibodies responded to the limited subregion of viral gp51, a common B cell epitope. This finding provides significant information for antigen selection in BLV to use in antibody detection assays. Further studies are needed to evaluate the antigenicity of His-gp5156–110 and gp5133–301(full) as antigens for antibody detection assays using a larger number of bovine serum samples.

Bovine Leukemia Virus (BLV) is distributed worldwide and causes important economic losses on dairy farms. Currently, there are no effective vaccines or antivirals against BLV. Egg yolk antibodies (IgY) has many advantages over mammalian IgG. Despite the higher yields, they are non-invasively extracted from egg yolk, do not cross react against mammalian antigens or activate the mammalian complement system. In this work we evaluate the reactivity of Igy antibodies against Bovine Leukemia Virus p24 core protein and against the whole virus particle. Hens were immunized by intramuscular inoculation with purified p24 or the virus particle until the development of high antibody-titers. Total IgY was purified from egg yolks by ammonium sulfate precipitation. The purified egg yolk antibodies strongly reacted with BLV particles from a persistently infected cell line, with supernatants from ex vivo cultures of PBMCs from natural infected animals and also with purified p24 by both ELISA and Western blot. These data suggest that chicken IgY may be a suitable platform to produce large amounts of anti-BLV antibodies for diagnostic systems. Furthermore, the use of IgY for passive immunization against BLV infection should also be explored in order to develop new strategies to control the disease in cattle.

Bovine leukemia virus (BLV) was detected and genotyped in a population of 201 dairy cattle from central Mexico. Using a commercial indirect enzyme-linked immunosorbent assay (iELISA) kit, 118 polymerase chain reaction (PCR)-positive and BLV antibody-positive samples were identified; the concordance between tests was substantial. A phylogenetic study of 27 partial sequences of the env gene gp30 was performed. Four mutations were detected involving the PXXP motif in the cytoplasmic domain of the transmembrane protein. This study provided evidence of the efficacy of PCR for the detection of BLV and demonstrated the presence of genotype 1 BLV in Mexico.

ABSTRACT Bovine leukemia virus (BLV) infects cattle around the world and presents in commercial bovine products. Several studies have suggested that BLV may play a role in breast oncogenesis. This study aimed to determine the risk factors for BLV infection and the presence of the BLV gene in breast tissue. A total of 100 formalin-fixed and paraffin-embedded breast tissue specimens were collected (50 confirmed cancer samples and 50 negative samples). DNA was extracted from breast tissues, and nested PCR was done to detect the tax gene of BLV. Immunohistochemical staining for ER, PR, Her2/neu, and Ki-67 was applied. Bovine leukemia virus DNA was detected in 16% of breast cancer tissue samples and in only 4% of tissue samples without cancer. No statistically significant association was reported between the presence of BLV and tumor grade, stage, or LN metastasis. A high percentage of positivity (100%, 88%, and 75%) was reported for ER, PR, and Ki-67 in BLV-positive cancer samples, respectively. There was a significant association between the BLV tax gene and breast cancer in Egyptian women. Thus, there is a need to control BLV transmission to humans from cattle, and further investigations about its risk related to public health are highly required.

Bovine leukemia virus (BLV) causes enzootic leukemia - a chronic infectious disease occurring against the background of embedding the virus in the genome of B-lymphocytes and leading to malignization, invasion of tumor cells in organs and the formation of tumors. The disease is common in the United States, Japan, and Asia. In Russia, up to 30% is infected with BLV. Moreover, there is evidence of the presence of antibodies to the BLV virus in some groups of people, and the relationship between BLV and cancer in humans is widely discussed. All this indicates an urgent need to study BLV and create breeds resistant to it. The development of approaches to solving this problem is complicated by the fact that the receptor through which the infection is carried out is still unknown. Recently, it has been suggested that the virus penetrates the animal's lymphocytes using the CD209 molecule. In this paper, we propose a genome editing system based on CRISPR/Cas9 to get a knockout for this gene. We assume that animals obtained using the presented genome editing system will be resistant to infection with the bovine leukemia virus.

Bovine leukemia virus (BLV) is a virus that infects cattle around the world and is very similar to the human T-cell leukemia virus (HTLV), which causes adult T-cell leukemia/lymphoma (ATL). Recently, presence of BLV DNA and protein was demonstrated in commercial bovine products and in humans. BLV DNA is generally found at higher rates in humans who have or will develop breast cancer, according to research done with subjects from several countries. These findings have led to a hypothesis that BLV transmission plays a role in breast cancer oncogenesis in humans. Here we summarize the current knowledge in the field.

Bovine leukemia virus (BLV) is a retrovirus that infects cattle and is associated with an increase in secondary infections. The objective of this study was to analyze the effect of BLV infection on cell viability, apoptosis and morphology of a bovine mammary epithelial cell line (MAC-T), as well as Toll like receptors (TLR) and cytokine mRNA expression. Our findings show that BLV infection causes late syncytium formation, a decrease in cell viability, downregulation of the anti-apoptotic gene Bcl-2, and an increase in TLR9 mRNA expression. Moreover, we analyzed how this stably infected cell line respond to the exposure to Staphylococcus aureus (S. aureus), a pathogen known to cause chronic mastitis. In the presence of S. aureus, MAC-T BLV cells had decreased viability and decreased Bcl-2 and TLR2 mRNA expression. The results suggest that mammary epithelial cells infected with BLV have altered the apoptotic and immune pathways, probably affecting their response to bacteria and favoring the development of mastitis.

Bovine leukemia virus (BLV) and human T-lymphotropic virus type 1 (HTLV-1) are closely related δ-retroviruses that induce hematological diseases. HTLV-1 infects about 15 million people worldwide, mainly in subtropical areas. HTLV-1 induces a wide spectrum of diseases (e.g., HTLV-associated myelopathy/tropical spastic paraparesis) and leukemia/lymphoma (adult T-cell leukemia). Bovine leukemia virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and besides the prevention of transmission, the best option to reduce the prevalence of δ-retroviruses is vaccination. Here, we provide an overview of the different vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.